The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030, predicts [Roots Analysis]

 

Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed review of the overall landscape of the non-invasive cancer diagnostics market. 

§  An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019.

§  An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics.

§  An analysis of the initiatives of big pharma players.

§  A detailed acquisition target analysis.

§  Elaborate profiles of the key players engaged in this domain.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of Tumor Marker

§  ctDNA

§  cfDNA

§  CTCs

§  Exosomes

§  Others

 

§  Application

§  Diagnosis / Early Diagnosis

§  Patient Monitoring

§  Recurrence Monitoring

 

§  Target Cancer Indication

§  Breast Cancer

§  Lung Cancer

§  Colorectal Cancer

§  Prostate Cancer

§  Bladder Cancer

§  Melanoma

§  Gastric Cancer

§  Pancreatic Cancer

§  Ovarian Cancer

§  Others

 

§  End Users

§  Hospitals

§  Research Institutes

§  Others

 

§  Key Geographical Regions 

Press Release: Variation 1 (Format 2)

 

§  North America

§  Europe

§  Asia-Pacific

§  Rest of the World

 

Key companies covered in the report:

§  Amoy Diagnostics

§  DiaCarta

§  HaploX Biotechnology

§  NeoGenomics

§  QIAGEN

§  Swift Biosciences

§  Sysmex Inostics

§  Thermo Fisher Scientific

 

For more information, please click on the following link: 

https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

 

Other recent offerings

1.     DNA-Encoded Libraries: Platforms and Services Market

2.     Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

3.     In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)

1.     Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more